Literature DB >> 27220573

[Chinese guideline for percutaneous coronary intervention(2016)].

.   

Abstract

Year:  2016        PMID： 27220573     DOI： 10.3760/cma.j.issn.0253-3758.2016.05.006

Source DB:  PubMed          Journal:  Zhonghua Xin Xue Guan Bing Za Zhi        ISSN： 0253-3758


× No keyword cloud information.
  32 in total

Review 1.  Advance for Cardiovascular Health in China.

Authors:  Yihua Bei; Chao Shi; Zhongrong Zhang; Junjie Xiao
Journal:  J Cardiovasc Transl Res       Date:  2018-12-07       Impact factor: 4.132

2.  Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity.

Authors:  Xiao-Yan Nie; Jun-Lei Li; Yong Zhang; Yang Xu; Xue-Li Yang; Yu Fu; Guang-Kai Liang; Yun Lu; Jian Liu; Lu-Wen Shi
Journal:  J Zhejiang Univ Sci B       Date:  2017 Jan.       Impact factor: 3.066

3.  Development of local clinical practice guidelines in the real world: an evolving scene in China.

Authors:  Joey Sw Kwong; Xin Sun
Journal:  Heart Asia       Date:  2017-06-16

4.  Efficacy and safety of Shen-Yuan-Dan capsules for peri-procedural myocardial injury following percutaneous coronary intervention: study protocol for a randomized, double-blind, placebo-controlled trial.

Authors:  Xiang Li; Xiao-Lei Lai; Yu-Tong Fei; Ju-Ju Shang; Qi Zhou; Xue-Yan Sun; Wen-Long Xing; Si-Han Jia; Hong-Xu Liu
Journal:  Ann Transl Med       Date:  2019-03

5.  Admission glycemic variability correlates with in-hospital outcomes in diabetic patients with non-ST segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Gong Su; Tao Zhang; Hongxia Yang; Wenlong Dai; Lei Tian; Hong Tao; Tao Wang; Shuhua Mi
Journal:  Anatol J Cardiol       Date:  2018-06       Impact factor: 1.596

Review 6.  Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis.

Authors:  Wen-Juan Xiu; Hai-Tao Yang; Ying-Ying Zheng; Yi-Tong Ma; Xiang Xie
Journal:  Cardiol Res Pract       Date:  2018-07-24       Impact factor: 1.866

7.  Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial.

Authors:  Xiujin Shi; Yunnan Zhang; Yi Zhang; Ru Zhang; Baidi Lin; Jialun Han; Wenzheng Li; Zhenwei Fang; Jialin Yan; Yifan Wang; Ze Zheng; Yuan Lv; Yang Lin
Journal:  Front Cardiovasc Med       Date:  2021-06-16

8.  [The value of cytochrome P4502C19 gene assay for anti-platelet therapy after PCI in stable angina patients with left main coronary artery lesions].

Authors:  Xiaofang Zheng; Liming Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-02-29

9.  Efficacy and safety of quadruple therapy including tirofiban in the treatment of Chinese NSTE-ACS patients failing to receive timely percutaneous coronary intervention.

Authors:  Lan Li; Zhenrong Ge; Dengke Zhang; Jun Kuang; Xiang Ma; Shubin Jiang
Journal:  Drug Des Devel Ther       Date:  2017-11-21       Impact factor: 4.162

10.  One-year Outcomes in Patients with ST-segment Elevation Myocardial Infarction Caused by Unprotected Left Main Coronary Artery Occlusion Treated by Primary Percutaneous Coronary Intervention.

Authors:  Hai-Wei Liu; Ya-Ling Han; Quan-Min Jin; Xiao-Zeng Wang; Ying-Yan Ma; Geng Wang; Bin Wang; Kai Xu; Yi Li; Shao-Liang Chen
Journal:  Chin Med J (Engl)       Date:  2018-06-20       Impact factor: 2.628
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.